Journal
CLINICAL CANCER RESEARCH
Volume 21, Issue 1, Pages 7-9Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-14-1660
Keywords
-
Categories
Funding
- NATIONAL CANCER INSTITUTE [R01CA141208, R01CA149501] Funding Source: NIH RePORTER
- NCI NIH HHS [R01 CA149501, R01CA141208, R01 CA141208, R01CA149501] Funding Source: Medline
Ask authors/readers for more resources
A phase I trial of PF-03084014, an oral reversible gamma-secretase inhibitor, in solid tumor malignancies shows drug tolerability in patients. Evidence of Notch pathway inhibition was demonstrated in peripheral blood. A surprisingly high rate of response was seen in desmoid tumors, a rare but sometimes locally aggressive sarcoma. (C) 2014 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
